CURE Pharmaceutical Subsidiary Completes Critical Milestone
CURE Pharmaceutical announced its subsidiary Oak Therapeutics completed a milestone as part of their research contract with the National Institutes of Health and National Institute of Allergy and Infectious Diseases to develop 300mg of Isoniazid in a rapidly dissolving Oral Dissolvable Strip as an antituberculosis treatment.
CURE Pharmaceutical (OTCQB:CURR) announced its subsidiary Oak Therapeutics completed a milestone as part of their research contract with the National Institutes of Health and National Institute of Allergy and Infectious Diseases (NIH, NIAID) to develop 300mg of Isoniazid in a rapidly dissolving Oral Dissolvable Strip (ODS) as an antituberculosis treatment.
As quoted in the press release:
Under the Phase I contract issued to Oak by the NIAID in May 2016, Oak sought to establish the technical merit, feasibility and commercial potential for the reformulation of isoniazid, an oral antibacterial prescription medicine for the prevention and treatment of Tuberculosis, as an ODS. Oak has created a novel formulation using encapsulation technologies, suitable matrix components, flavoring ingredients and other ODS formulation parameters to produce a product prototype containing 300mg of Isoniazid, that is both rapidly dissolving and mucoadhesive. This represents an industry-first, and a significant advance to CURE’s proprietary CureFilmTM drug delivery platform.
Patient adherence is a substantial health issue that is significantly magnified when dealing with long term treatments for diseases such as tuberculosis, the second most common infectious cause of death worldwide after HIV. A significant factor in suboptimal adherence may be the formulation of the drug. Furthermore, with Isoniazid included in the Best Practices for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics for 2015, isoniazid is an ideal candidate for reformulation as an ODS.